82 FR 18465 - National Cancer Institute; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 82, Issue 74 (April 19, 2017)
National Institutes of Health
Federal Register Volume 82, Issue 74 (April 19, 2017)
| Page Range | 18465-18466 | |
| FR Document | 2017-07842 |
[Federal Register Volume 82, Number 74 (Wednesday, April 19, 2017)] [Notices] [Pages 18465-18466] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-07842] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications/contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications/contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; HPV Review. Date: May 10, 2017. [[Page 18466]] Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W530, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Shamala K. Srinivas, Ph.D., Associate Director, Office of Referral, Review, and Program Coordination, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W530, Bethesda, MD 20892-9750, 240-276-6442, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Immunotherapy Trials Network. Date: May 18, 2017. Time: 2:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W102, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Shakeel Ahmad, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W102, Bethesda, MD 20892-9750, 240-276-6349, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; Technical Evaluation Panel #1. Date: May 23, 2017. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W260, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892-9750, 240-276-7684, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; Technical Evaluation Panel #2. Date: May 24, 2017. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W260, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Nadeem Khan, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892-9750, 240-276-7684, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Drug Resistance 1. Date: June 27-28, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878. Contact Person: Michael B. Small, Ph.D., Chief, Program and Review Extramural Staff Training Office, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W412, Bethesda, MD 20892-9750, 240-276-6438, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Drug Resistance 2. Date: June 27-28, 2017. Time: 8:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878. Contact Person: Wlodek Lopaczynski, MD, Ph.D., Assistant Director, Office of the Director, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W514, Bethesda, MD 20892-9750, 240-276-6340, [email protected]. Name of Committee: National Cancer Institute Initial Review Group; Subcommittee I--Transition to Independence. Date: June 14-15, 2017. Time: 8:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: Crown Plaza National Airport, 1480 Crystal Drive, Arlington, VA 22202. Contact Person: Delia Tang, MD, Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602, Bethesda, MD 20892-9750, 240-276-6456, [email protected]. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: April 13, 2017. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017-07842 Filed 4-18-17; 8:45 am] BILLING CODE 4140-01-P
![Federal Register / Vol. 82, No. 74 / Wednesday, April 19, 2017 / Notices 18465
6. Investigate associations between refinement of clinical diagnosis of ZIKV week until the partner has two negative
ZIKV infection in utero or in infancy infection in a setting in which testing consecutive tests for ZIKV or the
and hearing loss and other physical, and/or results might not be readily pregnancy ends. At all study visits, male
neurologic, and neurodevelopmental available. partners will complete visit-specific
outcomes at 6 months of age. 4. Assess the duration of viremia questionnaires and provide samples for
7. Estimate survival of infants born to following ZIKV infection and laboratory testing.
ZIKV infected mothers. investigate risk factors (such as
Secondary research questions we aim All newborns of mothers participating
sociodemographics, comorbidities, and in the study will be followed every
to address with the ZEN Colombia study co-infections) associated with prolonged
are: other week from birth to 6 months of
viremia among pregnant women, men, age. At all visits, infants will receive
1. Identify risk factors for ZIKV and infants with laboratory-confirmed
infection in pregnant women, partners national recommended clinical care (at
ZIKV infection in blood. birth and clinic visits at 1, 2, 3, and 6
and infants. A spectrum of risk factors
will be explored, including mosquito The project aims to enroll months), provide samples for laboratory
bites and mosquito bite preventive approximately 5,000 women, 1,250 male testing, and mothers will complete
measures, sexual transmission, partners, and 4,500 newborns. Pregnant study-specific questionnaires about
sociodemographic characteristics, and women will be recruited in the first infant ZIKV symptoms. Infants will also
medical risk factors. The results of this trimester of pregnancy for study have cranial ultrasounds at birth, their
analysis will provide information on the enrollment, followed by assessments head circumference measured (birth, 72
reduction in risk associated with during pregnancy (every other week hours, 1, 2, 3, and 6 months of age), and
adherence to recommended preventive until 32 weeks gestation and monthly enhanced hearing/vision tests at 1 and
measures and risk factors for infection thereafter), and at or within 72 hours of 6 months old. For mothers and their
in pregnant women. delivery. At all visits, participants will infants, relevant information collected
2. Identify characteristics associated complete visit-specific questionnaires. as part of clinical care will be abstracted
with taking preventive measures In addition to the questionnaires, at all from medical records. Study results will
(mosquito bite prevention, sexual pregnancy and delivery visits, be used to guide recommendations
transmission) against contracting Zika participants will receive Colombian made by both INS and CDC to prevent
virus among pregnant women and their national recommended clinical care and ZIKV infection; to improve counseling
partners. The results of this analysis provide samples for laboratory testing. of patients about risks to themselves,
will assist in targeting education or Male partners will be recruited their pregnancies, their partners, and
intervention to individuals at greatest around the time of the pregnant their infants; and to help agencies
risk for Zika infection. partners’ study enrollment, followed by prepare to provide services to affected
3. Describe symptoms associated with monthly visits until his pregnant children and families. Participation in
ZIKV and estimate the positive partner reaches the third trimester this study is voluntary. The total
predictive value of certain symptoms or (approximately 27 weeks gestation). If estimated annualized burden hours are
constellations of symptoms in pregnant the male partner contracts ZIKV during 19,415, and there are no costs to
women, men, and infants to allow for this time, visits will occur every other participants other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of Average
Number of responses burden per
Respondents Form name respondents per response
respondent (in hours)
Pregnant women ............................................. Pregnant women eligibility questionnaire ...... 3,125 1 5/60
Pregnant women enrollment questionnaire ... 2,500 1 35/60
Adult symptom questionnaire ......................... 2,500 15 10/60
Pregnant women follow-up questionnaire ...... 2,500 8 15/60
Infant symptoms questionnaire ...................... 2,250 14 10/60
Male partners .................................................. Male partner eligibility questionnaire ............. 2,500 1 5/60
Male enrollment questionnaire ....................... 625 1 25/60
Adult symptom questionnaire ......................... 625 7 10/60
Leroy A. Richardson, DEPARTMENT OF HEALTH AND as amended. The grant applications/
Chief, Information Collection Review Office, HUMAN SERVICES contract proposals and the discussions
Office of Scientific Integrity, Office of the could disclose confidential trade secrets
Associate Director for Science, Office of the National Institutes of Health or commercial property such as
Director, Centers for Disease Control and patentable material, and personal
Prevention. National Cancer Institute; Notice of information concerning individuals
[FR Doc. 2017–07879 Filed 4–18–17; 8:45 am] Closed Meetings associated with the grant applications/
BILLING CODE 4163–18–P Pursuant to section 10(d) of the contract proposals, the disclosure of
jstallworth on DSK7TPTVN1PROD with NOTICES
Federal Advisory Committee Act, as which would constitute a clearly
amended (5 U.S.C. App.), notice is unwarranted invasion of personal
hereby given of the following meetings. privacy.
The meetings will be closed to the Name of Committee: National Cancer
public in accordance with the Institute Special Emphasis Panel; HPV
provisions set forth in sections Review.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Date: May 10, 2017.
VerDate Sep<11>2014 15:06 Apr 18, 2017 Jkt 241001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\19APN1.SGM 19APN1](https://thefederalregister.org/doc/82_FR_18539/page/1.svg)
![18466 Federal Register / Vol. 82, No. 74 / Wednesday, April 19, 2017 / Notices
Time: 11:00 a.m. to 2:00 p.m. Place: Gaithersburg Marriott ACTION: 60-Day Notice and request for
Agenda: To review and evaluate contract Washingtonian Center, 9751 Washingtonian comments; Revision of Information
proposals. Boulevard, Gaithersburg, MD 20878. Collection Request: 1670–0015.
Place: National Cancer Institute Shady Contact Person: Michael B. Small, Ph.D.,
Grove, 9609 Medical Center Drive, Room Chief, Program and Review Extramural Staff SUMMARY: The Department of Homeland
7W530, Rockville, MD 20850 (Telephone Training Office, Division of Extramural Security (DHS or the Department),
Conference Call). Activities, National Cancer Institute, NIH,
Contact Person: Shamala K. Srinivas,
National Protection and Programs
9609 Medical Center Drive, Room 7W412,
Ph.D., Associate Director, Office of Referral, Bethesda, MD 20892–9750, 240–276–6438, Directorate (NPPD), Office of
Review, and Program Coordination, Division smallm@mail.nih.gov. Infrastructure Protection (IP),
of Extramural Activities, National Cancer Name of Committee: National Cancer Infrastructure Security Compliance
Institute, NIH, 9609 Medical Center Drive, Institute Special Emphasis Panel; Cancer Division (ISCD), will submit the
Room 7W530, Bethesda, MD 20892–9750, Drug Resistance 2. following Information Collection
240–276–6442, ss537t@nih.gov. Date: June 27–28, 2017. Request to the Office of Management
Name of Committee: National Cancer Time: 8:00 a.m. to 3:00 p.m. and Budget (OMB) for review and
Institute Special Emphasis Panel; Cancer Agenda: To review and evaluate grant clearance in accordance with the
Immunotherapy Trials Network. applications. Paperwork Reduction Act of 1995. DHS
Date: May 18, 2017. Place: Gaithersburg Marriott proposes to remove five of the six
Time: 2:00 p.m. to 5:00 p.m. Washingtonian Center, 9751 Washingtonian
Agenda: To review and evaluate grant instruments previously approved to
Boulevard, Gaithersburg, MD 20878.
applications. Contact Person: Wlodek Lopaczynski, MD, support the Chemical-terrorism
Place: National Cancer Institute Shady Ph.D., Assistant Director, Office of the Vulnerability Information (CVI) program
Grove, 9609 Medical Center Drive, Room Director, Division of Extramural Activities, under the Chemical Facility Anti-
7W102, Rockville, MD 20850 (Telephone National Cancer Institute, NIH, 9609 Medical terrorism Standards (CFATS)
Conference Call). Center Drive, Room 7W514, Bethesda, MD regulations, 6 CFR 27.400. DHS also
Contact Person: Shakeel Ahmad, Ph.D., 20892–9750, 240–276–6340, lopacw@ proposes to extend this collection with
Scientific Review Officer, Research Programs mail.nih.gov. revisions to reduce the estimated
Review Branch, Division of Extramural Name of Committee: National Cancer burden for the remaining instrument in
Activities, National Cancer Institute, NIH, Institute Initial Review Group; Subcommittee
9609 Medical Center Drive, Room 7W102, this collection.
I—Transition to Independence.
Bethesda, MD 20892–9750, 240–276–6349, DATES: Comments are encouraged and
Date: June 14–15, 2017.
ahmads@mail.nih.gov. Time: 8:00 a.m. to 1:00 p.m. will be accepted until June 19, 2017.
Name of Committee: National Cancer Agenda: To review and evaluate grant This process is conducted in accordance
Institute Special Emphasis Panel; Technical applications. with 5 CFR 1320.8.
Evaluation Panel #1. Place: Crown Plaza National Airport, 1480 ADDRESSES: Interested persons are
Date: May 23, 2017. Crystal Drive, Arlington, VA 22202. invited to submit comments on the
Time: 10:00 a.m. to 5:00 p.m. Contact Person: Delia Tang, MD, Scientific
Agenda: To review and evaluate contract
proposed revision to, and extension of,
Review Officer, Research Technology and
proposals. Contract Review Branch, Division of
this approved information collection
Place: National Cancer Institute Shady Extramural Activities, National Cancer through the Federal eRulemaking Portal
Grove, 9609 Medical Center Drive, Room Institute, NIH, 9609 Medical Center Drive, at http://www.regulations.gov. All
7W260, Rockville, MD 20850 (Telephone Room 7W602, Bethesda, MD 20892–9750, submissions received must include the
Conference Call). 240–276–6456, tangd@mail.nih.gov. words ‘‘Department of Homeland
Contact Person: Nadeem Khan, Ph.D., (Catalogue of Federal Domestic Assistance Security’’ and the docket number DHS–
Scientific Review Officer, Research Program Nos. 93.392, Cancer Construction; 2017–0015. Except as provided below,
Technology and Contract Review Branch, 93.393, Cancer Cause and Prevention comments received will be posted
Division of Extramural Activities, National Research; 93.394, Cancer Detection and
Cancer Institute, NIH, 9609 Medical Center
without alteration at http://
Diagnosis Research; 93.395, Cancer www.regulations.gov, including any
Drive, Room 7W260, Bethesda, MD 20892– Treatment Research; 93.396, Cancer Biology
9750, 240–276–7684, nadeem.khan@nih.gov. personal information provided.
Research; 93.397, Cancer Centers Support;
Name of Committee: National Cancer 93.398, Cancer Research Manpower; 93.399,
Comments that include trade secrets,
Institute Special Emphasis Panel; Technical Cancer Control, National Institutes of Health, confidential commercial or financial
Evaluation Panel #2. HHS) information, CVI,1 Sensitive Security
Date: May 24, 2017. Information (SSI),2 or Protected Critical
Dated: April 13, 2017.
Time: 10:00 a.m. to 5:00 p.m. Infrastructure Information (PCII) 3
Agenda: To review and evaluate contract Melanie J. Pantoja, should not be submitted to the public
proposals. Program Analyst, Office of Federal Advisory regulatory docket. Please submit such
Place: National Cancer Institute Shady Committee Policy. comments separately from other
Grove, 9609 Medical Center Drive, Room [FR Doc. 2017–07842 Filed 4–18–17; 8:45 am]
7W260, Rockville, MD 20850 (Telephone
comments in response to this notice.
Conference Call).
BILLING CODE 4140–01–P Comments containing trade secrets,
Contact Person: Nadeem Khan, Ph.D., confidential commercial or financial
Scientific Review Officer, Research information, CVI, SSI, or PCII should be
Technology and Contract Review Branch, DEPARTMENT OF HOMELAND appropriately marked and packaged in
Division of Extramural Activities, National SECURITY
Cancer Institute, NIH, 9609 Medical Center 1 For more information about CVI see 6 CFR
Drive, Room 7W260, Bethesda, MD 20892– [Docket No. DHS–2017–0015] 27.400 and the CVI Procedural Manual at http://
jstallworth on DSK7TPTVN1PROD with NOTICES
9750, 240–276–7684, nadeem.khan@nih.gov. www.dhs.gov/xlibrary/assets/chemsec_cvi_
Notice of Request for Revision to and proceduresmanual.pdf.
Name of Committee: National Cancer 2 For more information about SSI see 49 CFR part
Institute Special Emphasis Panel; Cancer Extension of a Currently Approved
1520 and the SSI Program Web page at http://
Drug Resistance 1. Information Collection for Chemical- www.tsa.gov.
Date: June 27–28, 2017. Terrorism Vulnerability Information 3 For more information about PCII see 6 CFR part
Time: 8:00 a.m. to 5:00 p.m. 29 and the PCII Program Web page at http://
Agenda: To review and evaluate grant AGENCY:National Protection and www.dhs.gov/protected-critical-infrastructure-
applications. Programs Directorate, DHS. information-pcii-program.
VerDate Sep<11>2014 15:06 Apr 18, 2017 Jkt 241001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\19APN1.SGM 19APN1](https://thefederalregister.org/doc/82_FR_18539/page/2.svg)
Document Created: 2018-11-14 09:43:29
Document Modified: 2018-11-14 09:43:29
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | May 10, 2017. | |
| FR Citation | 82 FR 18465 |
2026 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR